Total Payments
$20,908
2024 Payments
$20,459
Companies
17
Transactions
49
Medicare Patients
1,284
Medicare Billing
$174,960
Payment Breakdown by Category
Other$19,200 (91.8%)
Food & Beverage$1,349 (6.5%)
Travel$356.69 (1.7%)
Education$2.75 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,200 | 13 | 91.8% |
| Food and Beverage | $1,349 | 32 | 6.5% |
| Travel and Lodging | $356.69 | 2 | 1.7% |
| Education | $2.75 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $12,875 | 18 | $0 (2024) |
| Lilly USA, LLC | $7,585 | 7 | $0 (2024) |
| CALLIDITAS THERAPEUTICS US INC. | $113.96 | 1 | $0 (2024) |
| PFIZER INC. | $68.61 | 4 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $39.14 | 3 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $33.29 | 2 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $25.33 | 2 | $0 (2019) |
| AKEBIA THERAPEUTICS INC | $25.03 | 1 | $0 (2024) |
| GENZYME CORPORATION | $24.96 | 1 | $0 (2022) |
| Allergan Inc. | $23.63 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20,459 | 27 | Boehringer Ingelheim Pharmaceuticals, Inc. ($12,714) |
| 2023 | $155.72 | 3 | Boehringer Ingelheim Pharmaceuticals, Inc. ($140.38) |
| 2022 | $24.96 | 1 | GENZYME CORPORATION ($24.96) |
| 2020 | $13.53 | 1 | NxStage Medical, Inc. ($13.53) |
| 2019 | $55.50 | 4 | PFIZER INC. ($31.12) |
| 2018 | $107.57 | 7 | PFIZER INC. ($37.49) |
| 2017 | $92.24 | 6 | Boehringer Ingelheim Pharmaceuticals, Inc. ($21.29) |
All Payment Transactions
49 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $118.58 | General |
| Category: DIABETES | ||||||
| 10/21/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $2.38 | General |
| 10/21/2024 | Travere Therapeutics, Inc. | — | Education | In-kind items and services | $0.37 | General |
| 10/17/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $25.03 | General |
| Category: Nephrology | ||||||
| 10/09/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: DIABETES | ||||||
| 09/19/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $18.66 | General |
| Category: Immunology | ||||||
| 09/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $119.97 | General |
| Category: DIABETES | ||||||
| 08/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: DIABETES | ||||||
| 07/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $116.48 | General |
| Category: DIABETES | ||||||
| 07/10/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: Diabetes | ||||||
| 06/13/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: DIABETES | ||||||
| 06/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: DIABETES | ||||||
| 06/03/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: Diabetes | ||||||
| 05/22/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: DIABETES | ||||||
| 05/21/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: Diabetes | ||||||
| 05/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $102.65 | General |
| Category: DIABETES | ||||||
| 05/07/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $113.96 | General |
| Category: Nephrology | ||||||
| 05/06/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: Diabetes | ||||||
| 04/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,025.00 | General |
| Category: DIABETES | ||||||
| 04/08/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: DIABETES | ||||||
| 04/01/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: Diabetes | ||||||
| 03/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $116.70 | General |
| Category: DIABETES | ||||||
| 02/23/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $740.00 | General |
| Category: Diabetes | ||||||
| 02/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $76.57 | General |
| Category: DIABETES | ||||||
| 02/15/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,145.00 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 750 | 1,084 | $211,579 | $102,678 |
| 2022 | 10 | 321 | 478 | $95,415 | $48,779 |
| 2021 | 1 | 18 | 25 | $5,350 | $1,931 |
| 2020 | 7 | 195 | 251 | $51,447 | $21,572 |
Total Patients
1,284
Total Services
1,838
Medicare Billing
$174,960
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 141 | 152 | $46,056 | $20,371 | 44.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 110 | 195 | $30,420 | $18,055 | 59.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 146 | 256 | $28,160 | $15,514 | 55.1% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 17 | 45 | $22,500 | $12,322 | 54.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 120 | 167 | $31,730 | $12,176 | 38.4% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 14 | 32 | $13,760 | $7,333 | 53.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 57 | 57 | $14,250 | $6,871 | 48.2% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 22 | 42 | $6,300 | $2,796 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 44 | $5,896 | $2,469 | 41.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 17 | 22 | $5,830 | $2,383 | 40.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 33 | 41 | $6,150 | $2,305 | 37.5% |
| 81003 | Automated urinalysis test | Office | 2023 | 20 | 20 | $340.00 | $44.00 | 12.9% |
| 81002 | Urinalysis, manual test | Office | 2023 | 11 | 11 | $187.00 | $37.51 | 20.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 64 | 68 | $20,604 | $10,518 | 51.0% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 15 | 37 | $18,500 | $10,383 | 56.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 55 | 106 | $16,536 | $8,342 | 50.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 72 | 130 | $14,300 | $7,219 | 50.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 20 | 20 | $6,500 | $3,456 | 53.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 32 | 35 | $6,650 | $3,381 | 50.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 19 | 19 | $4,750 | $2,481 | 52.2% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2022 | 18 | 27 | $4,050 | $1,540 | 38.0% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2022 | 11 | 21 | $3,150 | $1,414 | 44.9% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2022 | 15 | 15 | $375.00 | $46.65 | 12.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 18 | 25 | $5,350 | $1,931 | 36.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 40 | 73 | $13,852 | $5,655 | 40.8% |
About Dr. Karim Attia, MD
Dr. Karim Attia, MD is a Internal Medicine healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2013. The National Provider Identifier (NPI) number assigned to this provider is 1801139217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Karim Attia, MD has received a total of $20,908 in payments from pharmaceutical and medical device companies, with $20,459 received in 2024. These payments were reported across 49 transactions from 17 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,200).
As a Medicare-enrolled provider, Attia has provided services to 1,284 Medicare beneficiaries, totaling 1,838 services with total Medicare billing of $174,960. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Nephrology
- Location Columbus, OH
- Active Since 04/03/2013
- Last Updated 01/12/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1801139217
Products in Payments
- JARDIANCE (Drug) $20,439
- TARPEYO (Drug) $113.96
- ELIQUIS (Drug) $68.61
- ZERBAXA (Drug) $26.53
- XARELTO (Drug) $25.33
- Vafseo (Drug) $25.03
- FABRAZYME (Biological) $24.96
- AVYCAZ (Drug) $23.63
- PRADAXA (Drug) $21.29
- Fabhalta (Drug) $18.66
- SOLIRIS (Drug) $18.33
- Kcentra (Biological) $17.27
- BENLYSTA (Biological) $15.34
- SAMSCA (Drug) $15.30
- ENTRESTO (Drug) $14.63
- SYSTEM ONE (Device) $13.53
- DIFICID (Drug) $12.61
- BRILINTA (Drug) $11.78
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Columbus
Anish Amin, M.d, M.D
Internal Medicine — Payments: $807,022
Internal Medicine $807,022
Dr. Alexa Meara, Md, MD
Internal Medicine — Payments: $377,655
Internal Medicine $377,655
Jayanta Mukherjee, Md, MD
Internal Medicine — Payments: $240,062
Internal Medicine $240,062
Dr. David Lo, M.d, M.D
Internal Medicine — Payments: $185,475
Internal Medicine $185,475
Narendranath Epperla, Md, MD
Internal Medicine — Payments: $184,240
Internal Medicine $184,240
Lucy Laperna, Do, DO
Internal Medicine — Payments: $133,632
Internal Medicine $133,632